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Dendritic cells (and/or macrophages) are
key transporters of antigen from extra-
lymphatic tissue to secondary lymphatic
organs. The phagocytized antigen is pre-
sented via MHC class II but not via class
I, except for infections by intracellular
viruses, bacteria, etc. (1–4).
Class II-negative cells (e.g., fibroblasts)
that get drained to secondary lymphatic
organs (including spleen) induce MHC
class I restricted CD8 T cells’ cell responses
as efficiently as dendritic cells (5–7).
So called crosspresentation is at least 105
times less efficient than direct presentation
and therefore is practically not achievable
under physiological conditions (5–8).
If antigen accumulates in the endoplas-
mic (ER) reticulum because of transport
problems, crosspresentation on to MHC
class I can be demonstrated. This requires
gigantic amounts of antigen accumulation
in the ER, but this process has so far been
difficult to quantitate in comparison to
direct presentation (9).
Positive demonstration of crosspresen-
tation in experiments is sometimes based
on use of excessive amounts of protein anti-
gen (e.g., OVA) and/or the use of unphysi-
ological (i.e., much too sensitive) detection
method, e.g., using very high frequencies
of transgenic T cells (e.g., OVA-specific
tgCD8+ T cells). In some experiments,
virus inactivation is not controlled prop-
erly, permitting abortive (but not virus
productive) infections that seemingly sug-
gest crosspresentation instead of direct
presentation [e.g., Ref. (8)].
An insulin-producing allogeneic cell
graft strictly transplanted under the kid-
ney capsule is accepted for more than
>200 days by the host, but is promptly
rejected if at the time of transplantation,
or a few days later, the same cells are also
given i.p. or i.v. (10) Once accepted, the
allogeneic strictly peripheral cell graft is
highly resistant to rejection by a trans-
planted corresponding allogeneic skin graft
(or dendritic cells). This skin graft is
rejected in a primary fashion, signaling
absence of direct or indirect priming by
the original allogeneic cell graft indicat-
ing absence of priming by the original cell
graft. This prompt skin rejection does not
cause rejection of the insulin-producing
cell graft (10).
A strictly extralymphatic (7) tumor
expressing a very strong and defined viral
antigen (similar to insulin-producing self-
beta-cells or allogeneic islet cells (10–12)
can grow successfully to become lethal
tumors. This depends on the condition
that at the time of syngeneic tumor cell
transplantation no (or too few) tumor
cells escape/or drain to secondary lym-
phatic organs (7). This potentially early
direct immunization is distinct from the
late process of metastasis to secondary
lymphatic organs that very often repre-
sent immune escape of tumor cells (e.g.,
MHC mutants, mutations of the T cell epi-
tope, barrier formation by fibrin, coagula-
tion, etc.)
DISCUSSION
DC transport antigen best to secondary
lymphatic organs but only in an MHC
class II associated fashion except of course
if the DC is productively or abortively
infected. The localization in or strictly
outside of secondary lymphatic organs
determines if and whether a CD8+ T
cell immune response is induced or not.
Crosspresentation of antigen to MHC class
I by DC or macrophages is an experimen-
tal artifact due to overdosage or uncon-
trolled new cell internal synthesis. Pure
crosspresentation is so inefficient, that it
is largely impractical for application and
therapeutic use against solid peripheral
tumors.
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